Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.35 |
| ▸ | HPGD | P15428 | 4/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 5/20 | 0.34 |
| ▸ | GSK3A | P49840 | 4/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11400671 | 0.85 | LMNA (0.39) | HSD17B10KDM4EL3MBTL1POLBALDH1A1 | |
| SCHEMBL2087785 | 0.74 | POLB (0.44) | KDM4EKMT2APOLBALDH1A1HPGD | |
| SCHEMBL3905435 | 0.69 | KMT2A (0.43) | HSD17B10KDM4EL3MBTL1KMT2AALDH1A1 | |
| SCHEMBL3904796 | 0.67 | SMN1; SMN2 (0.42) | HSD17B10L3MBTL1ALDH1A1GAAMAPT | |
| SCHEMBL3912090 | 0.67 | CA12 (0.41) | HSD17B10L3MBTL1KMT2APOLBALDH1A1 | |
| SCHEMBL3903904 | 0.67 | MAPT (0.39) | HSD17B10L3MBTL1KMT2AALDH1A1GAA | |
| SCHEMBL3912094 | 0.67 | CA12 (0.41) | HSD17B10L3MBTL1KMT2APOLBALDH1A1 | |
| SCHEMBL3904798 | 0.67 | SMN1; SMN2 (0.42) | HSD17B10L3MBTL1ALDH1A1GAAMAPT | |
| SCHEMBL4272728 | 0.66 | KMT2A (0.50) | HSD17B10KDM4EL3MBTL1KMT2APOLB | |
| SCHEMBL11410543 | 0.65 | KMT2A (0.45) | HSD17B10KDM4EL3MBTL1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1678171-B1 | 2-AMINO-4-THIAZOLONE-PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CYCLACEL LTD (GB) | 2016-09-14 | — | — | EP | disclosed |
| US-7902361-B2 | Pyrimidin-4-yl-3, 4-thione compounds and their use in therapy | CYCLACEL LIMITED (GB) | 2011-03-08 | — | — | US | disclosed |
| US-20070021452-A1 | Pyrimidin-4-YL-3, 4-thione compounds and their use in therapy | CYCLACEL LIMITED (GB) | 2007-01-25 | — | — | US | disclosed |
| EP-1678171-A1 | PYRIMIDIN-4-YL-3,4-THIONE COMPOUNDS AND THEIR USE IN THERAPY | Cyclacel Limited (GB) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005042525-A1 | PYRIMIDIN-4-YL-3, 4-THIONE COMPOUNDS AND THEIR USE IN THERAPY | CYCLACEL LIMITED (GB) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021452-A1 | Pyrimidin-4-YL-3, 4-thione compounds and their use in therapy | MSRB3, DHFR, CBR3 | HSD17B10 1426/4885KDM4E 2665/4885L3MBTL1 4058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.